Changing Predictors of Mortality Over Time From cART Start
- 1 November 2011
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 58 (3) , 269-276
Abstract
Objective To determine predictors of mortality and changes in those predictors over time on combination antiretroviral therapy (cART) in South Africa. Design A cohort study. Methods Using routine clinic data with up to 4 years follow-up after antiretroviral therapy initiation and with death ascertainment from a national vital statistics register, we used proportional hazards modeling to assess baseline and time-updated predictors of mortality and changes in strength of those predictors over time on cART. Furthermore, we compared CD4 count among individuals who died by duration on cART. Results Fifteen thousand sixty subjects (64% men, median CD4 count 127 cells/mm3) started antiretroviral therapy between January 2003 and January 2008. Over a median follow-up of 1.8 years, 2658 subjects died. The baseline characteristics of WHO stage, hemoglobin, CD4 count, HIV RNA level, and symptoms were all associated with mortality during the first 12 months of cART but lost association thereafter. However, time-updated factors of CD4 count, body mass index, symptoms, anemia, and HIV RNA suppression remained strong predictors of death. Most recent CD4 count before death rose from 71 during the first 3 months of cART to 175 cells per cubic millimeter after >3 years of cART. Conclusion Over 4 years of cART, risk of death declined and associations with mortality changed. An increase in CD4 count at death and changing associations with mortality may suggest a shift in causes of death, possibly from opportunistic infections to other infections and chronic illnesses.Keywords
This publication has 50 references indexed in Scilit:
- Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmesThe Lancet, 2010
- Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) StudyThe Journal of Infectious Diseases, 2010
- Hepatitis B and long-term HIV outcomes in coinfected HAART recipientsAIDS, 2009
- CD4+ Response and Subsequent Risk of Death Among Patients on Antiretroviral Therapy in Lusaka, ZambiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Trends in Mortality and Causes of Death Among Women With HIV in the United States: A 10-Year StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Comparison of CD4 Cell Count, Viral Load, and Other Markers for the Prediction of Mortality among HIV‐1–Infected Kenyan Pregnant WomenThe Journal of Infectious Diseases, 2009
- Variable Impact on Mortality of AIDS‐Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS‐Defining Conditions Are Created EqualClinical Infectious Diseases, 2009
- Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in MalawiThe Lancet, 2008
- Mortality trends in a new South Africa: Hard to make a fresh start1Scandinavian Journal of Public Health, 2007
- Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in ZambiaJAMA, 2006